ProMIS Neurosciences Announces Private Placement Financing
$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from...
Neuroscience
CORRECTING and REPLACING MedTech Innovator Unveils 64 Breakthrough Medtech Startups in its 2025 Cohort
—Top 4% of Global Applicants Selected to Compete for $800K in Non-Dilutive Funding and Unmatched Industry Access— —Up to 13...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July...
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses...
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar...
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNPTHE WOODLANDS, Texas, July...
Chen Institute and AAAS Announce Winner of 2024 AI Prize for AI Accelerated Research
Global research award celebrates transformative AI solutions in the fields of neuroscience, biochemistry, and climatology. REDWOOD CITY, Calif., July 17,...
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery
Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases...
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +12% USD) with core operating income1 up...
Expanded Research Tool to Crack the Code on Parkinson’s, the Fastest-Growing Neurodegenerative Disease
New collaboration between Aligning Science Across Parkinson's and Allen Institute creates a common language for visualizing data from Parkinson's and...
Virtua Health Successfully Goes Live on Oracle Cloud with Alithya as Strategic Implementation Partner
ALPHARETTA, Ga., July 16, 2025 /PRNewswire/ - Alithya is proud to announce the successful go-live of Oracle Cloud Enterprise Resource...
Second Edition of Ketamine-Assisted Therapy Training in Barcelona
BARCELONA, Spain , July 15, 2025 /PRNewswire/ -- Barcelona hosts pioneering training in ketamine-assisted psychotherapy The Ketamine Research Foundation (USA) and...
10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025
PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology,...
Study Finds Link Between Brain Injury and Criminal Behavior
Study shows criminality is associated with damage to a key brain pathway involved in emotional control and judgment AURORA, Colo.,...
LG Debuts Next-Generation Precision Medical AI
Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ --...
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH...
Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
- Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors Rome, Italy, 10th July 2025 – Angelini Ventures, the corporate...
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”),...
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted...